Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, November 2019
Adult
Male
Adolescent
Vaping
Lung Injury
Middle Aged
United States
Disease Outbreaks
3. Good health
Hospitalization
Young Adult
03 medical and health sciences
0302 clinical medicine
Humans
Female
Full Report
Centers for Disease Control and Prevention, U.S.
Aged
DOI:
10.15585/mmwr.mm6846e1
Publication Date:
2019-11-19T16:09:39Z
AUTHORS (63)
ABSTRACT
CDC, the Food and Drug Administration (FDA), state local health departments, public clinical stakeholders are investigating a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). As November 13, 2019, 49 states, District Columbia, two U.S. territories (Puerto Rico Virgin Islands) have reported 2,172 EVALI cases to including 42 (1.9%) EVALI-associated deaths. To inform surveillance, during 2019-20 influenza season, case report information supplied by states for hospitalized nonhospitalized patients with were analyzed using data collected as 5, 2019. Among 2,016 available on hospitalization status, 1,906 (95%) hospitalized, 110 (5%) not hospitalized. Demographic characteristics similar; most male (68% versus 65% patients), aged <35 years (78% 74% patients). These also similar use tetrahydrocannabinol (THC)-containing products (83% 84% Given similarity between patients, potential large numbers respiratory infections emerging difficulty in distinguishing from infections, CDC will no longer collect national patients. Further collection be at discretion individual state, local, territorial departments. Candidates outpatient management should normal oxygen saturation (≥95% while breathing room air), distress, comorbidities that might compromise pulmonary reserve, reliable access care, strong social support systems, able ensure follow-up within 24-48 hours initial evaluation seek medical care promptly if symptoms worsen. Health providers emphasize importance annual vaccination all persons ≥6 months, who (2,3).
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (4)
CITATIONS (63)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....